Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F18%3A10382043" target="_blank" >RIV/00179906:_____/18:10382043 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.2147/COPD.S145573" target="_blank" >https://doi.org/10.2147/COPD.S145573</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/COPD.S145573" target="_blank" >10.2147/COPD.S145573</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

Popis výsledku v původním jazyce

COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD carries a significant burden, with breathlessness frequently leading to a reduction in exercise capacity and changes that correlate with long-term patient outcomes and mortality. Implementation of an effective management strategy is required to reduce symptoms, preserve lung function, quality of life, and exercise capacity, and prevent exacerbations. However, current clinical practice frequently differs from published guidelines on the management of COPD. This review focuses on the current scientific evidence and expert opinion on the management of moderate COPD: the symptoms arising from moderate airflow obstruction and the burden these symptoms impose, how physical activity can improve disease outcomes, the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of inhaled corticosteroids in this disease. We emphasize the importance of maximizing bronchodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined patient groups.

Název v anglickém jazyce

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

Popis výsledku anglicky

COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD carries a significant burden, with breathlessness frequently leading to a reduction in exercise capacity and changes that correlate with long-term patient outcomes and mortality. Implementation of an effective management strategy is required to reduce symptoms, preserve lung function, quality of life, and exercise capacity, and prevent exacerbations. However, current clinical practice frequently differs from published guidelines on the management of COPD. This review focuses on the current scientific evidence and expert opinion on the management of moderate COPD: the symptoms arising from moderate airflow obstruction and the burden these symptoms impose, how physical activity can improve disease outcomes, the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of inhaled corticosteroids in this disease. We emphasize the importance of maximizing bronchodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined patient groups.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Chronic Obstructive Pulmonary Disease [online]

ISSN

1178-2005

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

neuvedeno

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

12

Strana od-do

45-56

Kód UT WoS článku

000419078800001

EID výsledku v databázi Scopus

2-s2.0-85038941422